New ASH Summit Encourages Practical, Elevated Dialogue on Emerging Immunotherapies
The ASH Summit on Emerging Immunotherapies for Hematologic Diseases program co-chairs Drs. Catherine Bollard, Rodrigo Calado, Sergio Giralt, and Jeffrey Miller share their
Novel Insights From Comprehensive Genomic Profiling of T Cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that helps expand understanding of T-cell acute lymphoblastic leukemia biology.
Dr. Raje and Dr. Yee look at the RVD regimen (lenalidomide, bortezomib, and dexamethasone) as standard of care in newly diagnosed multiple myeloma.
Dr. Raje and Dr. Yee cover efforts to identify new pathways to treat multiple myeloma relapse.
Dr. Raje and Dr. O'Donnell discuss the combination of monoclonal antibody therapies targeting the PD-1 receptor with approved therapies such as pomalidomide to treat multiple myeloma.
Dr. Raje and Dr. Yee covers the DETERMINATION trial, which will provide greater clarity on how long to use maintenance lenalidomide and whether longer maintenance will narrow the gap in PFS between upfront and deferred transplant approaches.
Drs. Raje, Yee, and Lohr discuss the development of a new tool for exploring the complexity of multiple myeloma through circulating myeloma cells, which could replace bone marrow biopsies and permits analysis to be performed at multiple time points.
Dr. Raje, Dr. Yee and Dr. O'Donnell discuss various daratumumab combinations that have emerged as options for the treatment of multiple myeloma.
Dr. Raje reviews a study that compares daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone alone for the treatment of patients with multiple myeloma who have received one prior line of therapy.
Dr. Raje and Dr. O'Donnell look at a study that proves there is a role for salvage autologous stem cell transplantation in the second-line setting for multiple myeloma patients.
Dr. Raje and Dr. Yee discuss a study that looks at the use of pembrolizumab in combination with lenalidomide or pomalidomide to treat multiple myeloma as a form of checkpoint inhibition, a new important tool in cancer treatment.
Dr. O'Donnell and Dr. Raje look at a study that attempts to understand the biology of clonal plasma cells in low levels or MRD states after induction therapy, which can lead to a better understanding of chemoresistance and more effective therapies for MM.
January-February 2018Volume 15, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology